報價延遲最少15分鐘:2026/06/06 00:38 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
16.52 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.58/-2.89
|
|
企業價值
341.79M
|
| 資產負債 |
|
每股賬面淨值
2.06
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata. |
